Comments
MSN Laboratories Pvt. Ltd. (MSN) is initiating phase III clinical trial of Molnupiravir capsules for the treatment of Covid-19 in India.
MSN received clinical trial approval from the Drug Controller General of India to perform Molnupiravir Capsules’ efficacy and safety study on mild-to-moderate Covid-19 patients last week.
Hyderabad-based MSN will start its clinical trials in more than 40 sites across the country.
Clinical trials will be performed on more than 2,400 subjects suffering from mild-to-moderate Covid-19.
Molnupiravir is an experimental drug having antiviral properties and is currently under clinical stage study for Covid-19 treatment.
MSN R&D team has developed both the API and formulation, is expecting to launch after successful conclusion of clinical study followed by regulatory approval, according to a release.
As part of the Covid treatment range, MSN has already launched Favilow (Favipiravir) in the strengths of 200mg, 400mg & 800mg, Oselow (Oseltamivir) as 75 mg capsules and licensed Baridoz (Baricitinib) with Eli Lilly,
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.